Neil D. Gross, MD, FACS, discusses how treatment with neoadjuvant cemiplimab followed by surgery with curative intent prolonged event-free survival in patients with stage II to IV cutaneous squamous cell carcinoma, adding that these outcomes warrant further investigation in a randomized setting.